PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
38322349,Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy.,2024,"Zhao, Huan","Revvity Inc., Waltham, MA 02451, USA.",None
38304857,"RELAY, Erlotinib Plus Ramucirumab in Untreated, ",2024,"Carlsen, Michelle","Eli Lilly and Company, Indianapolis, Indiana.",None
38245456,Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.,2024,"Zeuner, Harald; Xue, Cloris","F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Mississauga, Canada.",matthew.krebs@manchester.ac.uk.
38239813,A retrospective study of ensartinib-treated ,2023,"Yuan, Xiaobin; Wang, Yang; Yang, Min; Wu, Pengxiang; Chen, Hui; Yun, Yu; Shen, Zhilin; Ji, Dong; Ma, Yongbin; Ding, Lieming","Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, Zhejiang, 311100, China.",None
38222108,T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis.,2024/Jan/19,"Li, Chengcheng; Zhu, Xin; Wang, Guoqiang; Cai, Shangli","Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.",None
38176113,"Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.",2024/Jan/15,"Imaizumi, Tomoyoshi; Shimada, Itsuro; Satake, Yoshiki; Yamaki, Susumu; Koike, Takanori; Nigawara, Takahiro; Kaneko, Osamu; Amano, Yasushi; Mori, Kenichi; Yamanaka, Yosuke; Nakayama, Ayako; Nishizono, Yoshihiro; Shimazaki, Masashi; Nagashima, Takeyuki; Kuramoto, Kazuyuki","Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. Electronic address: tomoyoshi.imaizumi@astellas.com.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.; Tsukuba Research Center, Astellas Pharma Inc.; 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.",tomoyoshi.imaizumi@astellas.com.
38159809,"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.",2024,"Okpara, Chinyere E; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati","Eisai Ltd., Hatfield, United Kingdom.; Eisai Inc., Nutley, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",chihyang@ntu.edu.tw.
38131189,Incidence of interstitial lung disease in patients with breast cancer: a nationwide database study in Japan.,2024,"Onoue, Tomohiro; Hashimoto, Wataru","Daiichi Sankyo Co., Ltd, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, 140-8710, Japan.",None
38114357,Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.,2024,"Prawitz, Thibaud; Lin, Huamao M; Hong, Jin-Liern; Tan, Min; Proskorovsky, Irina; Hernandez, Luis; Jin, Shu; Zhang, Pingkuan; Lin, Jianchang","Evidera, Inc, Paris, France.; Takeda Development Center Americas, Inc., Lexington, MA. Electronic address: Mark.Lin@Takeda.com.; Takeda Development Center Americas, Inc., Lexington, MA.; Evidera, Inc, Lexington, MA.; Evidera, Inc, Lexington, MA.; Takeda Pharmaceuticals America, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.",Mark.Lin@Takeda.com.
38101437,"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.",2024,"Yang, Zhenfan","Dizal Pharmaceutical, Shanghai, China. Electronic address: pamela.yang@dizalpharma.com.",pamela.yang@dizalpharma.com.
38100106,Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.,2023/Dec/01,"Nishimura, Kunihiro; Hiraoka, Manabu","Xcoo Inc, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",None
38092014,Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.,2024/Apr/01,"Spanoudi, Filio; Dimitriadis, Ioannis","MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece.; MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece.",None
38076998,Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R.,2023/Nov/29,"Gurvich, Nadia; Zhang, Christie; Tan, Seng-Lai; Hsu, Jonathan","Marengo Therapeutics, 840 Memorial Dr, Cambridge, MA 02139 USA.; Marengo Therapeutics, 840 Memorial Dr, Cambridge, MA 02139 USA.; Marengo Therapeutics, 840 Memorial Dr, Cambridge, MA 02139 USA.; Marengo Therapeutics, 840 Memorial Dr, Cambridge, MA 02139 USA.",None
38062129,"The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.",2024,"Pan, Wentao","Ascentage Pharma (Suzhou) Co Ltd, 218 Xinghu Street, Suzhou, Jiangsu Province, China.",zhaohy@sysucc.org.cn.
38049664,The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.,2024,"McCoach, Caroline E","Genentech Inc, South San Francisco, CA, USA.",trever.bivona@ucsf.edu.
38035705,Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.,2023,"Weidle, Ulrich H; Birzele, Fabian","Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; weidle49@t-online.de.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland fabian.birzele@roche.com.",fabian.birzele@roche.com.
38023699,Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety.,2023,"Yang, Joo-Sung; Kim, Kyungjin",ST Pharm Co. Ltd. Seoul South Korea.; ST Pharm Co. Ltd. Seoul South Korea.,None
38008032,Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.,2024,"Arrieta, Oscar","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",christian.rolfo@mssm.edu.
38001689,C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.,2023/Nov/15,"Pérez-Pitarch, Alejandro","Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.",None
38001589,Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating ,2023/Nov/08,"Diels, Joris; Schioppa, Claudio A; Sermon, Jan; Rahhali, Nora; Adamczyk, Agnieszka; Penton, James","Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen-Cilag Ltd., 92130 Issy-les-Moulineaux, France.; Janssen-Cilag Ltd., 28042 Madrid, Spain.; Janssen-Cilag Ltd., High Wycombe HP12 4EG, UK.",None
37992595,"Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).",2023,"Alatorre-Alexander, Jorge; Araujo, Luiz Henrique","Health Pharma Professional Research, Mexico City, Mexico.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.",egaron@mednet.ucla.edu.
37986065,Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.,2023/Nov/20,"Yasamineh, Saman; Gholizadeh, Omid","Free Researcher, Viro & Biotech, Tehran, Iran. Yassaman124@gmail.com.; Free Researcher, Viro & Biotech, Tehran, Iran. ogholizade1374@gmail.com.",ogholizade1374@gmail.com.
37963637,Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.,2023,"Kober, Christina; Schmees, Norbert; Roese, Lars; Roehn, Ulrike; Bader, Benjamin; Stoeckigt, Detlef; Prinz, Florian; Gorjánácz, Mátyás; Roider, Helge Gottfried; Olesch, Catherine; Leder, Gabriele; Irlbacher, Horst; Lesche, Ralf; Lefranc, Julien; Oezcan-Wahlbrink, Mine; Carretero, Rafael; Weinmann, Hilmar; Hartung, Ingo V; Kreft, Bertolt; Gutcher, Ilona","Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.; Bayer AG, Pharmaceutical Division, Berlin, Germany.",m.platten@dkfz-heidelberg.de.
37956762,Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).,2024/Jan/01,"Xu, Xin; Chen, Jia; Wang, Guan; Zhang, Xiaojuan; Li, Qiang; Zhou, Xiaobo; Guo, Fengying; Li, Min","Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China. Electronic address: xuxin@huahaipharm.com.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.; Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.",xuxin@huahaipharm.com.
37933916,"Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.",2024/Feb/15,"Froelich, Carolin","Roche Pharma AG, Grenzach-Wyhlen, Germany.",None
37930454,Unknown,2023/Nov/06,"Zeevaart, Jan Rijn","Radiochemistry, The South African Nuclear Energy Corporation, Pelindaba, Hartebeespoort, 0240, South Africa.",maryke.kahts@smu.ac.za.
37929602,Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.,2024/Jan/02,"Lei, Lei; Louie, Michael J","Esperion Therapeutics, Ann Arbor, MI (L.L., M.J.L.).; Esperion Therapeutics, Ann Arbor, MI (L.L., M.J.L.).",None
37923723,Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.,2023/Nov/03,"Cojoc, Hanne; Kuryk, Lukasz","Valo Therapeutics Oy, Viikinkaari 6, Helsinki, Finland, 00790, Helsinki, Finland.; Valo Therapeutics Oy, Viikinkaari 6, Helsinki, Finland, 00790, Helsinki, Finland.",vincenzo.cerullo@helsinki.fi.
37920468,The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.,2023,"Subra, Frédéric; Richetta, Clémence; Deprez, Eric; Delelis, Olivier","Université Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.; Université Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.; Université Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.; Université Paris-Saclay, ENS Paris-Saclay, CNRS UMR 8113, IDA FR3242, Laboratory of Biology and Applied Pharmacology (LBPA), Gif-sur-Yvette, France.",None
37903504,Association between pathologic response and survival after neoadjuvant therapy in lung cancer.,2024,"Tran, Mia; Bushong, Judith; Cai, Junliang; Devas, Vipul; Neely, Jaclyn; Balli, David","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",jtaube1@jhmi.edu.
37889752,KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.,2023/Nov/28,"Wohlhieter, Corrin A","Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.",sergei.koralov@nyulangone.org.
37860193,Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.,2023,"Kiss, Zoltán; Hódi, Gábor; Polányi, Zoltán; Kovács, Krisztina; Knollmajer, Kata; Szabó, Tamás G; Berta, Andrea; Rokszin, György; Abonyi-Tóth, Zsolt; Barcza, Zsófia","MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; RxTarget Ltd., Szolnok, Hungary.; RxTarget Ltd., Szolnok, Hungary.; Syntesia Ltd, Budapest, Hungary.",None
37852183,Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing.,2023/Oct/17,"Rivera, Victor M","Theseus Pharmaceuticals, Inc., Cambridge, MA 02142, USA.",jrp94@psu.edu.
37848682,Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.,2023,"McCarthy, Derrick; Horton, Holly; Kieffer-Kwon, Philippe; Ding, Jian; Baeuerle, Patrick A; Hofmeister, Robert; Gutierrez, Dario A; Tighe, Robert","TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA.; TCR2 Therapeutics, Inc., 100 Binney Street, Suite 710, Cambridge, MA, 02142, USA. rob.tighe1973@gmail.com.",rob.tighe1973@gmail.com.
37843054,Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.,2024/Feb/01,"Wiens, Jacinta","Merck Pharmaceuticals, Rahway, New Jersey, USA.",None
37817505,Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.,2023,"Chiumente, Marco","Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Turin, Italy.",None
37814061,ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.,2023,"Sausen, Mark","Personal Genome Diagnostics (LabCorp), Baltimore, MD, USA.",jdancey@ctg.queensu.ca.
37801674,"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.",2023/Dec/20,"Ohwada, Shoichi; Koyama, Kumiko; Inoue, Tatsuya; Li, Li; Patel, Parul; Mostillo, Joseph; Tanaka, Yoshimi; Sternberg, David W; Sellami, Dalila","Daiichi Sankyo Co, Ltd, Tokyo, Japan.; Daiichi Sankyo Co, Ltd, Tokyo, Japan.; Daiichi Sankyo RD Novare Co, Ltd, Tokyo, Japan.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.",None
37792849,Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.,2023/Nov/28,"Michelis, Fotios V; Joseph, Jacinth","Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.; Methodist Healthcare Blood and Marrow Transplant Center, Memphis, TN.",None
37783102,Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.,2023/Dec/05,"Jang, Sun Young; Kwak, Eun Joo; Lee, Sun Hoe; Byun, Joo-Yun; Kim, Yu-Yon; Ahn, Young Gil","Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.",insukim@skku.edu.
37776107,Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.,2024,"Russu, Alberto; Sun, Yu-Nien; Zhou, Honghui","Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.; Cognigen Division, Simulations-Plus Company, Buffalo, New York, USA.; Jazz Pharmaceuticals, Philadelphia, Pennsylvania, USA.",None
37773318,ALK fusions in the pan-cancer setting: another tumor-agnostic target?,2023/Sep/29,"Janku, Filip","Monte Rosa Therapeutics, Boston, MA, USA.",rkurzrock@mcw.edu.
37768658,Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.,2023/Nov/01,"Bedard, Philippe L; Wu, Benjamin; Patil, Namrata S; Jin, Yanling; Hoang, Tien; Mendus, Diana; Wen, Xiaohui; Meng, Raymond","Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Clinical Pharmacology, Genentech Inc, South San Francisco, California.; Biomarkers, Genentech Inc, South San Francisco, California.; Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.; Clinical Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.; Safety Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.",None
37754495,Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.,2023/Aug/30,"Tomás-Guillén, Elena; Monterde, Josep","Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.; Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.",None
37744306,Real-World Response and Outcomes in Patients With NSCLC With ,2023,"Lin, Huamao M; Hong, Jin-Liern; Yin, Yu; Jin, Shu; Lin, Jianchang; Mehta, Minal","Global Evidence and Outcomes Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Global Evidence and Outcomes Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Oncology Statistics, Takeda Pharmaceuticals United States, Inc., Lexington, Massachusetts.; Clinical Science, Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Oncology Statistics, Takeda Pharmaceuticals United States, Inc., Lexington, Massachusetts.; Clinical Science, Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.",None
37743366,Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.,2023,"Miyazaki, Isao; Ishida, Keiji; Kato, Masanori; Suzuki, Tatsuya; Wakayama, Kentaro; Fujita, Hidenori; Khodos, Inna; Yamada, Yukari; Funabashi, Kaoru; Chang, Qing; Ohkubo, Shuichi; Yano, Wakako; Terada, Ryuichiro; Giuliano, Claudio; Bonifacio, Annalisa; de Stanchina, Elisa; Lovati, Emanuela; Iwasawa, Yoshikazu","Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.; Helsinn Healthcare SA, Lugano, Switzerland.; Helsinn Healthcare SA, Lugano, Switzerland.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Helsinn Healthcare SA, Lugano, Switzerland.; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.",somwarr@mskcc.org.
37741832,Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.,2023/Sep/23,"Gierke, Sarah; Wongchenko, Matthew J; Yan, Yibing","Center for Advanced Light Microscopy, Genentech Inc., South San Francisco, USA.; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.",aditya.murthy@gilead.com.
37735252,Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma.,2023/Sep/21,"Lee, Hankyu; Lee, Hyerim; Jeon, Doyong","L-Base Company, Seoul, South Korea.; L-Base Company, Seoul, South Korea.; L-Base Company, Seoul, South Korea. David.jeon@l-base.com.",jeoungd@kangwon.ac.kr.
37731641,Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.,2023,"Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh","Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Bengaluru, Karnataka, India.",None
37729426,Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.,2023/Dec/15,"Christensen, James G; Tang, Tracy T","Mirati Therapeutics, Inc., San Diego, California.; Vivace Therapeutics, Inc., San Mateo, California.",None
37716872,Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.,2023,"Pacaud, Lida; Akram, Muhammad","Legend Biotech USA Inc., Somerset, NJ.; Legend Biotech USA Inc., Somerset, NJ.",sundar.jagannath@mountsinai.org.
37704610,De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8.,2023/Sep/13,"Overed-Sayer, Catherine; Finch, Donna K; Lowe, David","Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.",dabaker@uw.edu.
37704469,"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).",2023,"List, Alan F","Precision BioSciences, Inc., Durham, NC, USA.",amer.zeidan@yale.edu.
37699333,Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.,2023/Sep/11,"Topp, Brian G; Mayawala, Kapil; De Alwis, Dinesh P; Rubin, Eric; Snyder, Alexandra","Merck & Co., Inc, Rahway, NJ, USA. Electronic address: brian.topp@merck.com.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.",brian.topp@merck.com.
37695273,The evolution of payer management of oncology drugs in the United States between 2017 and 2022.,2023,"Runyan, Anne; Yi, Janice; Honcz, Joe","Envision Pharma Group, San Diego, CA.; Envision Pharma Group, San Francisco, CA.; Envision Pharma Group, Milford, CT.",None
37691854,A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.,2023,"Pankov, Aleksandr; Junttila, Melissa R; Daemen, Anneleen; Friedman, Lori S","ORIC Pharmaceuticals, South San Francisco, California.; ORIC Pharmaceuticals, South San Francisco, California.; ORIC Pharmaceuticals, South San Francisco, California.; ORIC Pharmaceuticals, South San Francisco, California.",None
37684239,Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.,2023/Sep/08,"Coombs, Justin","Carina Biotech, Level 2 Innovation & Collaboration Centre, UniSA Bradley Building, Adelaide, SA, 5001, Australia.",simon.barry@adelaide.edu.au.
37677918,"A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).",2023,"Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu","Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.",zhangli@sysucc.org.cn.
37671649,Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.,2023,"Walter, Roland B","Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.",None
37664025,Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.,2023,"Kopyltsov, Evgeny; Burgents, Joseph E; Perini, Rodolfo; He, Cixin; Okpara, Chinyere E; McKenzie, Jodi","State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States.; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States.; Biostatistics, Eisai Inc., Nutley, NJ, United States.; Clinical Research, Eisai Ltd., Hatfield, United Kingdom.; Clinical Research, Eisai Inc., Nutley, NJ, United States.",None
37656263,Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.,2023,"Baratta, Cristina","Medical Affairs, Oncology, Jazz Pharmaceuticals, Mississauga, ON, Canada.",devon.boyne1@ucalgary.ca.
37651655,"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.",2023/Dec/20,"Eaton, Lamar; Chisamore, Michael J; Soumaoro, Ibrahima","Genmab US, Princeton, NJ.; Merck & Co, Inc, Rahway, NJ.; Genmab US, Princeton, NJ.",None
37649319,IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers.,2023,"Xie, Wenchuan; Zhao, Jing; Wang, Yanan; Wang, Guoqiang; Zhu, Xin; Lin, Kequan; Lu, Huafei; Han, Yusheng; Li, Leo; Cai, Shangli","Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.; Burning Rock Biotech, Guangdong, China.",None
37648084,PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs.,2023,"Zhou, Jingsong","Shanghai Yizhong Biotechnical Co., Ltd., Shanghai, China. Electronic address: zjs@yizhongpharma.com.",eddiedong8@hotmail.com.
37639589,Leveraging intracellular ALDH1A1 activity for selective cancer stem-like cell labeling and targeted treatment via in vivo click reaction.,2023/Sep/05,"Luu, Long M","Iria Pharma, Champaign, IL 61820.",None
37634830,Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts.,2023/Oct/15,"Zhong, Zhangyan; Chen, Yu","GenePharma, Suzhou 215123, PR China.; GenePharma, Suzhou 215123, PR China.",fhmeng@suda.edu.cn.
37626086,Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.,2023/Aug/25,"Endou, Hitoshi","J-Pharma Co., Ltd, Yokohama, Kanagawa, 230-0046, Japan.",ykanai@pharma1.med.osaka-u.ac.jp.
37608772,Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.,2023,"Akturk, Guray; Scott, Ely","Translational Molecular Biomarkers, Merck & Co Inc, Rahway, NJ, USA.; Translational Pathology, Translational Sciences and Diagnostics/Translational Medicine/R&D, Bristol Myers Squibb, Princeton, NJ, USA.",None
37608771,Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.,2023,"Akturk, Guray; Ely, Scott; Hytopoulos, Evangelos","Translational Molecular Biomarkers, Merck & Co Inc, Kenilworth, NJ, USA.; Translational Pathology, Translational Sciences and Diagnostics/Translational Medicine/R&D, Bristol Myers Squibb, Princeton, NJ, USA.; iRhythm Technologies Inc., San Francisco, CA, USA.",None
37606995,Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.,2023/Nov/01,"Menon, Roopika; Heuckmann, Johannes M","DISCO Pharmaceuticals GmbH, Cologne, Germany.; DISCO Pharmaceuticals GmbH, Cologne, Germany.",None
37593227,"AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.",2023,"Li, Wenting; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle","Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.",None
37574538,Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.,2023/Aug/14,"Murray, Suzanne; Péloquin, Sophie; Lazure, Patrice","AXDEV Group Inc, 210-8, Place du Commerce, Brossard, Québec, J4W 3H2, Canada. murrays@axdevgroup.com.; AXDEV Group Inc, 210-8, Place du Commerce, Brossard, Québec, J4W 3H2, Canada.; AXDEV Group Inc, 210-8, Place du Commerce, Brossard, Québec, J4W 3H2, Canada.",murrays@axdevgroup.com.
37563310,Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.,2023,"Folkersen, Lasse","Nucleus Genomics ltd, New York, NY, USA.",j.peters@imperial.ac.uk.
37563300,Generation of precision preclinical cancer models using regulated in vivo base editing.,2024,"Kadina, Anastasia P; Walker, John A; Holden, Kevin","Synthego Corporation, Redwood City, CA, USA.; Synthego Corporation, Redwood City, CA, USA.; Synthego Corporation, Redwood City, CA, USA.",lud2005@med.cornell.edu.
37548831,First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.,2023,"Li, Li; Gupta, Ravi G; Bushong, Judith","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mnishio@jfcr.or.jp.
37536935,Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.,2023,"Marcos Rubio, Alvaro; Everaert, Celine; Van Damme, Eufra; De Preter, Katleen","VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.",karim.vermaelen@ugent.be.
37531900,Blocking LTB,2023,"Xiao, Wei","State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co. Ltd., Lianyungang, Jiangsu 222001, PR China.",chunlizheng@126.com.
37516008,Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.,2023,"Raez, Luis E","Memorial Healthcare System, Pembroke Pines, FL, USA.",nagasakm@hs.uci.edu.
37508543,Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells.,2023/Jul/18,"Sadeghi, Tara","Cellenkos Inc., Houston, TX 77005, USA.",None
37499521,A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.,2023,"Sansil, Samer; Neuger, Anthony","Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.; Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.",andreas.saltos@moffitt.org.
37463106,SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.,2023/Jul/25,"Luo, Xiaolin; Das, Sudipto; Andresson, Thorkell","Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.; Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD 21702, USA.; Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD 21702, USA.",vassiliki.saloura@nih.gov.
37459541,Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.,2023/Jul/25,"Yan, Honghua; Zhou, Qianxiang; Ma, Liandong","Kintor Pharmaceutical Limited, Suzhou Industrial Park, Suzhuo 215123, China.; Kintor Pharmaceutical Limited, Suzhou Industrial Park, Suzhuo 215123, China.; Kintor Pharmaceutical Limited, Suzhou Industrial Park, Suzhuo 215123, China.",None
37452374,Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer.,2023/Jul/14,"Zhang, Zhihong; Lizaso, Analyn; Li, Bingsi; Wang, Chenyang; Li, Bing; Li, Xi","Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.",wangjun@pkuph.edu.cn.
37449205,Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.,2023,"Yi, Xiaohui","Bellicum Pharmaceuticals, Inc., Houston, TX, United States.",None
37441599,Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency.,2023,"Zhao, Jian","KOCHKOR Biotech, Inc., Shanghai, Shanghai 201406, China.",None
37437226,"Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.",2023,"Manoogian, Amanda","Partners Health Specialty Pharmacy, Boston, MA.",None
37422924,Lung tumor microphysiological system with 3D endothelium to evaluate modulators of T-cell migration.,2023,"Lamb, Mahdi; Griffin, Suzanne","Genomic Sciences, Research, Pharmaceutical R&D, GSK, Stevenage, UK.; Immuno-Oncology, Research, Pharmaceutical R&D, GSK, Stevenage, UK.",None
37420219,Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.,2023/Jul/07,"Zhang, Lei","Hebei Province Pharmaceutical Professional Inspector Corps (Hebei Provincial Vaccine Inspection Center), Shijiazhuang, China.",lyb.he@163.com.
37415224,Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.,2023/Jul/06,"Zhang, Yu; Ma, Sijia; Dai, Shang; Wang, Guoqiang; Lu, Huafei; Cai, Shangli","Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.; Burning Rock Biotech, Guangzhou, 510300, China.",403092@csu.edu.cn.
37398153,Unknown,2023/Jun/12,"Overed-Sayer, Catherine; Finch, Donna K; Lowe, David","Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.",None
37396870,In Silico Discovery of 5'-Modified 7-Deoxy-7-ethynyl-4'-thioadenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor.,2023/Jun/28,"Lee, Hyuk Woo","Future Medicine Company, Limited, Seongnam, Gyeonggi-do 13449, Republic of Korea.",None
37393762,"Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.",2023,"Xu, Ting; Xu, Mo; Zhi, Lihua; Liu, Qing; Wang, Ni","Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Biostatistic, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.",caicunzhoudr@163.com.
37390764,Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.,2023,"Graham, H; Butts, B D; Visseren-Grul, C","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.",egaron@mednet.ucla.edu.
37390632,Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I.,2023,"Peng, Li-Zeng","Jinan AISI Pharmaceutical Technology Co Ltd, Jinan 250104, PR China.",liuyqlab@163.com.
37385724,"Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.",2023,"Ansari, Sahar; Jacquemont, Celine; Topletz-Erickson, Ariel; Zhou, Peigen; Schmitt, Michael W","Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.; Seagen Inc, Bothell, Washington, USA.",acoveler@uw.edu.
37381723,Biological insights in non-small cell lung cancer.,2023/Jun/28,"Morrison, Blake","Sumitomo Pharma Oncology, Inc., Cambridge, MA and Lehi, UT 84043, USA.",None
37377611,Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.,2023,"Nishito, Yukari; Sonobe, Yukiko; Kayukawa, Yoko; Hashimoto, Eri; Takahashi, Mina; Fujii, Etsuko; Nishizawa, Takashi; Maruyama, Toru; Tsukada, Keisuke; Yabuki, Nami; Shimada, Mei; Kitazawa, Takehisa; Natori, Osamu; Sawada, Noriaki; Kato, Atsuhiko; Mizuno, Hideaki; Tsunoda, Hiroyuki","Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.",None
37355629,Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.,2023/Jun/24,"Rudin, Charles M; Bailis, Julie M; Bebb, Gwyn; Goldrick, Amanda; Umejiego, John","Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. rudinc@mskcc.org.; Oncology Research, Amgen Inc., South San Francisco, CA, USA.; Oncology TA-US, Amgen Inc., Thousand Oaks, CA, USA.; Oncology TA-US, Amgen Inc., Thousand Oaks, CA, USA.; Oncology TA-US, Amgen Inc., Thousand Oaks, CA, USA.",rudinc@mskcc.org.
37354546,Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.,2023/Jul/11,"Li, Na; Foody, JoAnne; Louie, Michael J","Esperion Therapeutics Inc, Ann Arbor, Michigan.; Esperion Therapeutics Inc, Ann Arbor, Michigan.; Esperion Therapeutics Inc, Ann Arbor, Michigan.",None
37352387,"MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.",2023/Oct/02,"Kong, Chao; Zhao, Qianqian; Weng, Weining; Ma, Linjie; Meng, Xun; Meng, Tao","Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; MabCare Therapeutics, Shanghai, China.",None
37348348,Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study).,2023,"Ding, L; Wang, Y; Yuan, X","Betta Pharmaceuticals Co., Ltd, Hangzhou, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.",zlyangyue@bjmu.edu.cn.
37343657,Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.,2023,"Hernandez-Martinez, Juan-Manuel; Arrieta, Oscar","Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico; CONACYT-Instituto Nacional de Cancerología, Mexico City, Mexico.; Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico. Electronic address: ogar@unam.mx.",ogar@unam.mx.
37341856,ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.,2023,"Sussell, Jesse; Lin, Chia-Wei; Ogale, Sarika","Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.",Vivek.Rudrapatna@ucsf.edu.
37335901,Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.,2023/Sep/07,"Brannman, Lance; Cotarla, Ion; Mulrooney, Tiernan","Oncology Business Unit, Global Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.; Oncology Business Unit, US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.; Oncology Business Unit, US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.",None
37329423,"Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.",2023,"Jen, Min-Hua","Eli Lilly and Company, Bracknell, UK.",jyshih@ntu.edu.tw.
37328119,Re-exposure of chitosan by an inhalable microsphere providing the re-education of TAMs for lung cancer treatment with assistant from sustained H,2023/Jul/25,"Zhang, Cong","Shanghai Frontier Health Pharmaceutical Technology Co., Ltd, People's Republic of China.",xiaojiang_235@163.com.
37318757,Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.,2023,"Daniel, Davey; Vaena, Daniel; Slater, Dennis; Staszewski, Harry; Fang, Bruno; Seneviratne, Lasika; Yu, Elaine; Price, Richard; Szado, Tania; Meyer, Craig S; Shah, Anuj; Ma, Esprit","OneOncology, Inc., Nashville, TN 37219, USA.; OneOncology, Inc., Nashville, TN 37219, USA.; OneOncology, Inc., Nashville, TN 37219, USA.; OneOncology, Inc., Nashville, TN 37219, USA.; OneOncology, Inc., Nashville, TN 37219, USA.; OneOncology, Inc., Nashville, TN 37219, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Janssen Pharmaceuticals of Johnson & Johnson, South San Francisco, CA 94080, USA.; Gilead Sciences, Inc., Foster City, CA 94404, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.",None
37310183,Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.,2023/Aug/03,"Desai, Ketul",Novartis Pharmaceuticals UK Limited.,None
37306665,Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis.,2023,"Vallow, Susan; Gilloteau, Isabelle; Chassot Agostinho, Andrea","Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.",None
37306623,Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.,2023,"Apple, Jon; Shenolikar, Rahul; De Silva, Kevin; Sun, Ping","AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, USA.; AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, USA.; AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, USA.; AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, USA.",None
37302522,"AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.",2023/Sep/05,"Meng, Tao; Ma, Linjie; Shen, Yi; Wang, Zhaohui; Pan, Rong; Wang, Mingqiao; Chen, Caiwei; Wang, Lijun; Zhang, Jianjian; Zhou, Biao; Liu, Shuhui; Meng, Xun","MabCare Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Abmart Inc, Shanghai, P.R. China.; Abmart Inc, Shanghai, P.R. China.; Abmart Inc, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.; Multitude Therapeutics, Shanghai, P.R. China.",None
37297026,Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS,2023/Jun/05,"Arkenau, Hendrik-Tobias","Ellipses Pharma, London W1J 8LG, UK.",None
37296463,Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.,2023/Jun/09,"Zhang, Jiao; Yang, Ying; Lin, Xiang; Zhu, Xiaoyu","Genecast Biotechnology Co., Ltd, Wuxi, 214104, China.; Genecast Biotechnology Co., Ltd, Wuxi, 214104, China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.",harry_ren@126.com.
37285629,Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.,2023,"Hsu, Hil; Younan, Diana; Suri, Gaurav; Chia, Victoria","Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Health Economics and Outcomes Research, Amgen Inc., 4 Uxbridge Business Park, Sanderson Road Uxbridge UB8 1DH, UK.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.",jhanelle.gray@moffitt.org.
37282666,Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.,2023/Oct/15,"Yao, Sheng; Qin, Mengmeng; Shen, Zhenwei; Yang, Jason","CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China.; CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China.; CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China.; CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China.",None
37278879,"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.",2023,"Oza, Amit; Mugundu, Ganesh","Princess Margaret Cancer Centre, Toronto, Canada.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Boston, MA, USA.",siqingfu@mdanderson.org.
37277734,Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.,2023/Jun/05,"Lazure, Patrice; Murray, Suzanne; Péloquin, Sophie","AXDEV Group Inc., 8, Place du Commerce, Suite 210, Brossard, Québec, J4W 3H2, Canada. lazurep@axdevgroup.com.; AXDEV Group Inc., 8, Place du Commerce, Suite 210, Brossard, Québec, J4W 3H2, Canada.; AXDEV Group Inc., 8, Place du Commerce, Suite 210, Brossard, Québec, J4W 3H2, Canada.",lazurep@axdevgroup.com.
37274265,Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage ,2023,"Szymczak, Sylwia; Szpurka, Anna M; Chao, Bo H","Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland.; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States.; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States.",Loxo@Lilly
37269687,"Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR",2023/Jul/15,"Gao, Biao; Gao, Peng","Jiangsu Hansoh Pharmaceutical Group CO., LTD., Lianyungang 222000, PR China.; Jiangsu Hansoh Pharmaceutical Group CO., LTD., Lianyungang 222000, PR China.",sgou@seu.edu.cn.
37251627,Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.,2023,"Chandrawansa, Kumari; Sandström, Per","Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.",None
37245409,Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC.,2023,"Coyle, Jayme","UES, Inc, Dayton, OH, USA.",yrojan@hsc.wvu.edu.
37212336,Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.,2023,"Ding, Jun; Zhao, Ronghua; Jia, Weiguo","Shanghai Virogin Biotech Co. Ltd., Shanghai, China.; Shanghai Virogin Biotech Co. Ltd., Shanghai, China.; Shanghai Virogin Biotech Co. Ltd., Shanghai, China.",None
37208130,Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.,2023,"Klar, Richard; Festag, Julia; Michel, Sven; Maaske, Andre; Jaschinski, Frank","Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.",mikael.pittet@unige.ch
37192591,ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression.,2023,"Zhai, Yifan","Ascentage Pharma (Suzhou) Co., Ltd, Suzhou, Jiangsu, China.",ssun@emory.edu.
37183528,Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.,2023,"Schwarzenberger, Paul","Merck & Co., Inc., Rahway, New Jersey, USA.",None
37182602,Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.,2023,"Tirunagaru, Vijaya G; Doebele, Robert C","Rain Oncology Inc., Newark, California.; Rain Oncology Inc., Newark, California.",ladanyim@mskcc.org.
37168563,A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma.,2023/May/19,"Xie, Wenchuan; Li, Chengcheng; Meng, Fanqi; Wang, Guoqiang; Zhao, Jing; Han, Yusheng; Cai, Shangli","Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.; Burning Rock Biotech, Guangdong 510300, P.R. China.",None
37164449,OncoVEX,2023,"Estrada, Juan; Zhan, Jinghui; Mitchell, Petia; Werner, Jonathan; Beltran, Pedro J; DeVoss, Jason; Cooke, Keegan S","Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; BridgeBio Pharma, Palo Alto, California, USA.; Amgen Inc, Thousand Oaks, California, USA.; Amgen Inc, Thousand Oaks, California, USA kcooke@amgen.com.",kcooke@amgen.com.
37163811,Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.,2023,"Yan, Tingting","Sichuan Good Doctor Panxi Pharmaceutical Co.,Ltd., Xichang 615000, China.",chenlijuan125@163.com.
37158938,"First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.",2023/May/08,"Kang, Xiaoyan; Xue, Shilin","Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.",zhaohy@sysucc.org.cn.
37125741,Recent advancement on albumin nanoparticles in treating lung carcinoma.,2023,"Dubey, Sunil Kumar","R&D Healthcare Division, Emami Ltd, Belgharia, Kolkata, India.",None
37118803,Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.,2023/Apr/28,"Hu, Jie; Liu, Fei; Jiang, Yong; Ge, Nan","Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.; Shanghai Allist Pharmaceutical Technology Co., Ltd, , Shanghai, China.",syuankaipumc@126.com.
37115550,Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.,2023/Apr/03,"Takeda, Kentaro","Data Science, Astellas Pharma Global Development, Inc, Northbrook, Illinois.",None
37111311,TEAD Inhibitors Sensitize KRAS,2023/Apr/06,"Calvet, Loreley; Noblet, Laurence; Sidhu, Sukhvinder","Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France.",None
37096188,Gumarontinib in patients with non-small-cell lung cancer harbouring ,2023,"Li, Meng","Biostatistic and Data Science, Haihe Biopharma Co., Ltd, Shanghai, China.",None
37094467,"bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.",2023,"Cai, Yiran; Sun, Wenjie; Zou, Xiao; Li, Bing; Zhang, Zhou; Cai, Shangli; Chuai, Shannon; Han, Yusheng","Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.; Burning Rock Biotech, Guangzhou, China.",dingzhih72@163.com.
37087886,Synthesis and evaluation of sulfonamide derivatives targeting EGFR,2023/May/01,"Yao, Han; Ren, Yuanyuan; Li, Xingshu","Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation and Research, China.; Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation and Research, China.; Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation and Research, China. Electronic address: lixsh@mail.sysu.edu.cn.",jiaxian@syphu.edu.cn.
37081523,ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.,2023/Apr/20,"Sarno, Francesca; Alonso, Carolina","Peaches Biotech, Madrid, Spain.; Peaches Biotech, Madrid, Spain.",rtoledo@vhio.net.
37077473,"Beyond antibody fucosylation: α-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy.",2023,"Mao, Changchuin; Gao, Wenda","Antagen Pharmaceuticals, Inc., Canton, MA 02021, USA.; Antagen Pharmaceuticals, Inc., Canton, MA 02021, USA.",None
37060507,Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway.,2023,"He, Yue; Cheng, Chunming; Yuan, Jingna; Wen, Zhuohao","Jinhang Bio-Science and Biotechnology Co. Ltd, Guangzhou, 510630, People's Republic of China.; Jinhang Bio-Science and Biotechnology Co. Ltd, Guangzhou, 510630, People's Republic of China.; Jinhang Bio-Science and Biotechnology Co. Ltd, Guangzhou, 510630, People's Republic of China.; Jinhang Bio-Science and Biotechnology Co. Ltd, Guangzhou, 510630, People's Republic of China.",yuanzq@gdut.edu.cn.
37049777,Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.,2023/Mar/28,"Kartsev, Victor","InterBioScreen Ltd., 85355 Moscow, Russia.",None
37025260,A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.,2023,"Zhang, Baolin","Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, MA, USA.",None
37024582,Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.,2023,"Rizvi, Naiyer","Synthekine, Inc., Menlo Park, CA, USA.",jgainor@mgh.harvard.edu.
37001859,Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.,2023,"Giorgadze, Davit; Li, Siyu; Li, Yuntong; Kaul, Manika; Quek, Ruben G W; Pouliot, Jean-Francois; Seebach, Frank; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra","LTD Multiprofile Clinic Consilium Medulla, Tbilisi, Georgia.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",tamta.makharadze@gmail.com.
36961477,Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.,2023/May/08,"Cuffel, Brian; Paracha, Noman; Goodman, Clifford","Bayer Pharmaceuticals, Basel, Switzerland.; Bayer Pharmaceuticals, Basel, Switzerland.; The Lewin Group, Inc., Falls Church, VA, USA.",None
36947734,Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in ,2023/May/10,"Gaur, Anil; Evans, Helen; Basu, Sumit","Novartis Healthcare Private Limited, Hyderabad, India.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
36944282,Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.,2023,"Greenland, Jonathan","Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada. Electronic address: jonathan.greenland@easternhealth.ca.",geoffrey.liu@uhn.ca.
36934059,Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1,2023,"List, Alan F","Precision BioSciences, Inc., Durham, NC, USA.",amer.zeidan@yale.edu.
36932463,Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview.,2023,"Romagnoli, Alessia","Territorial Pharmaceutical Service, Local Health Unit of Lanciano Vasto Chieti, Chieti, Italy.",None
36924737,"Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment.",2023,"Lu, Xiulian","Cisen Pharmaceutical Co., Ltd, Jining, 272000, China.",jnsljiang@163.com.
36921725,Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.,2023,"Datta, Dhrubajyoti; Charisse, Klaus; Manoharan, Muthiah","Alnylam Pharmaceuticals, 675 West Kendall, Cambridge, MA 02142, United States.; Alnylam Pharmaceuticals, 675 West Kendall, Cambridge, MA 02142, United States.; Alnylam Pharmaceuticals, 675 West Kendall, Cambridge, MA 02142, United States.",mariaj.alonso@usc.es.
36920856,Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders.,2023,"Hale, Sarah; Waters, Brittany","Takeda Pharmaceuticals U.S.A, Lexington, Massachusetts, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.",None
36900371,"Treatment Patterns, Testing Practices, and Outcomes in Patients with ",2023/Mar/03,"Samborska, Agnieszka","AstraZeneca Pharma Poland Sp.zo.o., 02-676 Warsaw, Poland.",None
36890302,Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer.,2023/Mar/08,"Martinez, Pablo; McCue, Shannon","Sumitomo Pharma Oncology, Inc, Cambridge, MA, USA.; Sumitomo Pharma Oncology, Inc, Cambridge, MA, USA.",christian.rolfo@mssm.edu.
36849197,PD-L1 gene amplification and focality: relationship with protein expression.,2023,"Murugesan, Karthikeyan; Elvin, Julia A; Huang, Richard S P","Cancer Genomics Research, Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.",jardimde@gmail.com.
36842467,MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.,2023,"Olson, Peter; Latven, Lisa; Yan, Xiaohong; Shazer, Ronald","Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.",kai.he@osumc.edu.
36841727,A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.,2023,"Sacher, Adrian","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",wade.t.iams@vumc.org.
36831009,Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives.,2023/Feb/06,"Alhazza, Mohammed Bader","John Hopkins Armco Healthcare, Dhahran 34465, Saudi Arabia.",None
36829154,"Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).",2023/Feb/24,"Si, Meimei; Geng, Huaize; Li, Hui; Kang, Xiaoyan","Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.",syuankai@cicams.ac.cn.
36820928,High dose isoleucine stabilizes nuclear PTEN to suppress the proliferation of lung cancer.,2023/Feb/23,"Wang, Chao; Li, Liang; Wang, Zhengzhong","State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co. Ltd., Lianyungang, 222002, Jiangsu, China.; State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co. Ltd., Lianyungang, 222002, Jiangsu, China.; State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co. Ltd., Lianyungang, 222002, Jiangsu, China.",yhwang@nwu.edu.cn.
36809334,The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures.,2023/Feb/21,"Clevers, Hans","Roche Pharma Research and early Development, Basel, Switzerland.",None
36808075,SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.,2023,"Li, Hui; Zhang, Juan; Peng, Yanyan","BeiGene (Shanghai) Co., Ltd, Shanghai, China.; BeiGene (Beijing) Co., Ltd, Beijing, China.; BeiGene (Shanghai) Co., Ltd, Shanghai, China.",syylwu@live.cn.
36789090,Safety Profiling of Tumor-targeted T Cell-Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip.,2023/Jan/05,"Kerns, Jordan S; Belgur, Chaitra; Kanellias, Marianne; Manatakis, Dimitris V; Barrile, Riccardo; Tien-Street, Will; Ewart, Lorna; Gjorevski, Nikolche; Cabon, Lauriane","Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Emulate Inc, Boston, United States.; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.",None
36775996,Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer.,2023,"Acheampong, Felix","Verve Therapeutics, Cambridge, Massachusetts, USA.",None
36768214,A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.,2023/Jan/18,"Hannani, Dalil; Leplus, Estelle; Laulagnier, Karine; Plumas, Joël","PDC*line Pharma, 38000 Grenoble, France.; PDC*line Pharma, 38000 Grenoble, France.; PDC*line Pharma, 38000 Grenoble, France.; PDC*line Pharma, 38000 Grenoble, France.",None
36753744,Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.,2023/Apr/04,"Kessler, Linda; Burrows, Francis","Kura Oncology, Inc., San Diego, California.; Kura Oncology, Inc., San Diego, California.",None
36751989,Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.,2023,"Emir, Birol; Iadeluca, Laura","Pfizer Inc., New York, USA.; Pfizer Inc., New York, USA.",None
36738928,"Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study.",2023,"Peng, Zheng; Yin, Lifeng; Ma, Chi","Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.",chenlk@sysucc.org.cn.
36736511,Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.,2023,"Ascierto, Paolo A","Melanoma, Cancer Immunotherapy and Development Therapeutics Unit Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale"", Napoli, Italy.",m.egeler@nki.nl.
36733927,"Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative ""cold"" triple-negative breast cancer.",2023,"Yuan, Jiandong; Zhang, Peizhuo","BrightGene Bio-Medical Technology Co., Ltd., Suzhou, 215123, PR China.; GenePharma Co., Ltd., Suzhou, 215123, PR China.",None
36725084,"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.",2023,"Li, Sunney; Fiore, Joseph; Acevedo, Angelic","Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.",neal.ready@duke.edu.
36701715,A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report.,2023/Jan/20,"Du, Haiwei","Burning Rock Biotech, Guangzhou, China.",None
36701651,"First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.",2023,"Shia, Chi-Sheng; Hsu, Pei; Pearce, Tillman E","OBI Pharma Inc, Taipei City, Taiwan.; OBI Pharma Inc, Taipei City, Taiwan.; OBI Pharma USA, Inc, San Diego, CA.",None
36701244,Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation.,2023/Feb/14,"McCulloch, William; Pearce, Cedric J; Oberliels, Nicholas H","Alba BioPharm Advisors, Inc., Raleigh, North Carolina 27614, United States.; Mycosynthetix, Inc., Hillsborough, North Carolina 27278, United States.; Ionic Pharmaceuticals, LLC, Watertown, Massachusetts 02472, United States.",None
36700864,Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.,2023/Apr/03,"Hettrick, Lisa; Maazi, Hadi; Revenko, Alexey S","Ionis Pharmaceuticals, Carlsbad, California.; Ionis Pharmaceuticals, Carlsbad, California.; Ionis Pharmaceuticals, Carlsbad, California.",None
36693125,Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.,2023/Apr/03,"Meng, Tao; Zhao, Qianqian; Shen, Yi; Fu, Guoxiang; Shi, Jing; Zhang, Yue; Wang, Zhaohui; Wang, Mingqiao; Pan, Rong; Ma, Linjie; Chen, Caiwei; Wang, Lijun; Zhou, Biao; Zhang, Hui; Zhang, Jianjian; Hu, Yi Peter; Liu, Shu-Hui; Meng, Xun","HySlink Therapeutics, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; D1 Medical Technology Company, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Abmart Inc., Xuhui District, Shanghai, China.; Abmart Inc., Xuhui District, Shanghai, China.; Abmart Inc., Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; HySlink Therapeutics, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; D1 Medical Technology Company, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.; Multitude Therapeutics, Xuhui District, Shanghai, China.",None
36691089,A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.,2023/Jan/23,"Lin, Yu-Ling","Agricultural Biotechnology Research Center, Academia Sinica, Taipei, 11529, Taiwan.",liaonms@nycu.edu.tw.
36689692,"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.",2023/Jun/01,"Zhang, Yiran; Pati, Amrita; Minocha, Mukul; Mukherjee, Sujoy; Goldrick, Amanda; Nagorsen, Dirk; Hashemi Sadraei, Nooshin","Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.",None
36669791,"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.",2023,"Hill, Andrew G; Jennens, Ross R; Ren, Yixin; Schmidt, Emmett V","Tasman Oncology Research Ltd, Southport, Queensland, Australia.; Epworth Healthcare, Richmond, Victoria, Australia.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.",rudinc@mskcc.org.
36669321,Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.,2023,"Lee, Adam; Yuan, Yong; Eccles, Laura J; Varol, Nebibe; Penrod, John R","Bristol Myers Squibb Pharmaceuticals Ltd, Sanderson Rd, Denham, Uxbridge, England.; Bristol Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA.; Bristol Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA.; Bristol Myers Squibb Pharmaceuticals Ltd, Sanderson Rd, Denham, Uxbridge, England.; Bristol Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA.",epopoff@broadstreetheor.com.
36650021,Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.,2023,"Huang, Richard S P; Li, Gerald; Schrock, Alexa; Graf, Ryon P; Zhang, Liangliang; Murugesan, Karthikeyan; Ross, Jeffrey S; Tolba, Khaled; Oxnard, Geoffrey R","Foundation Medicine Inc, Cambridge, Massachusetts, USA rhuang@foundationmedicine.com.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.",rhuang@foundationmedicine.com.
36646210,Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.,2023,"Tai, Yanfei; Ma, Xinjing; Shi, Wei","Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, People's Republic of China.; Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, People's Republic of China.; Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, People's Republic of China.",caicunzhoudr_@163.com.
36639770,Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.,2023/Jan/13,"Penrod, John R","Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.",andreayvonne.wolf@kgu.de.
36623238,Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.,2023,"Hopkins, Julia F; Murugesan, Karthikeyan; Kuang, Zheng; Huang, Richard S P; Albacker, Lee A","Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.",None
38644188,[DIAGNOSIS OF GENETIC VARIANT CARRIERS IN A PATIENT WITH ASYMPTOMATIC BIRT-HOGG-DUBÉ SYNDROME: A CASE REPORT].,2023,"Furuya, Mitsuko","Pathology Center, Genetic Lab Co. Ltd.",None
38405208,High-dose alectinib for ,2023,"Alatorre-Alexander, Jorge; Bhagawati-Prasad, Vijay; Shagan, Sarah M; Schleifman, Erica; Ruf, Thorsten; Mathisen, Michael S","Health Pharma Professional Research, Mexico City, Mexico.; F. Hoffmann-La Roche, Ltd., Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.",None
36572154,Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.,2023,"Yang, Xiaojing; Guo, Wei; Chew, Yap Ching; Kim, Juwan; Baek, Seunggul; Kim, Ik Soo","Zymo Research Corporation, Irvine, CA 92604, United States.; Zymo Research Corporation, Irvine, CA 92604, United States.; Zymo Research Corporation, Irvine, CA 92604, United States.; Pharma Research, Co, Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea.; Pharma Research, Co, Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea.; Pharma Research, Co, Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea.",kwonyj@uci.edu.
36571770,"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.",2023/Mar/17,"Helwig, Christoph","Merck Healthcare KGaA, Darmstadt, Germany.",None
36470334,Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model.,2023,"Percier, Pauline; Gérard, Pierre","InhaTarget Therapeutics, Rue Antoine de Saint-Exupéry 2, Gosselies, Belgium. Electronic address: pauline.lehebel@inhatarget.com.; InhaTarget Therapeutics, Rue Antoine de Saint-Exupéry 2, Gosselies, Belgium.",remi.rosiere@inhatarget.com.
36460584,Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.,2023,"Ogawa, Toru; Sadatsuki, Yasunari; Tsujino, Toshiaki","Market Access Oncology, Bayer Yakuhin, Ltd, Osaka, Japan. Electronic address: toru.ogawa@bayer.com.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.",toru.ogawa@bayer.com.
36459255,"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.",2023,"Der-Torossian, Hirak; Christensen, James G; Faltaos, Demiana; Potvin, Diane; Tassell, Vanessa; Chao, Richard","Mirati Therapeutics Inc., San Diego, CA, USA.; Mirati Therapeutics Inc., San Diego, CA, USA.; Mirati Therapeutics Inc., San Diego, CA, USA.; Mirati Therapeutics Inc., San Diego, CA, USA.; Mirati Therapeutics Inc., San Diego, CA, USA.; Mirati Therapeutics Inc., San Diego, CA, USA.",ckollmannsberger@bccancer.bc.ca.
36414192,Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.,2023,"Memaj, A; Nathan, F","Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; OneClinical, Bristol Myers Squibb, Princeton.",hossein.borghaei@fccc.edu.
36412002,Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.,2023,"Li, Jing; Su, Fei; Hu, Yingwen; Zhao, Xiaobin","Zhejiang Haichang Biotechnology Co., Ltd., Hangzhou, Zhejiang, 310000, P. R. China.; Zhejiang Haichang Biotechnology Co., Ltd., Hangzhou, Zhejiang, 310000, P. R. China.; The Whiteoak Group, Inc., Rockville, MD, 20855, USA.; The Whiteoak Group, Inc., Rockville, MD, 20855, USA.",None
36403367,"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.",2023,"Voisin, Anne Laure; Messayke, Sabine; Laghouati, Salim","Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.",sami.antoun@gustaveroussy.fr.
36394849,Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.,2023/Jan/01,"Dvorkin, Michael","Clinical Oncology Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation.",None
36376172,Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.,2023,"Lin, Huamao M; Wu, Yanyu; Yin, Yu; Niu, Huifeng; Curran, Eileen A; Humphries, Michael J","Takeda Development Center Americas, Inc., Lexington, MA. Electronic address: Mark.Lin@takeda.com.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Development Center Americas, Inc., Lexington, MA.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.",Mark.Lin@takeda.com.
36375120,NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.,2023/Mar/30,"Kelly, Aileen; McIntosh, Joel; Tenn-McClellan, Austin; Ambing, Eileen; Tan, Ying Siow; Lu, Hao; Gajewski, Stefan; Clifton, Matthew C; Yung, Stephanie; Robbins, Daniel W; Noviski, Mark","Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.; Nurix Therapeutics, Inc, San Francisco, CA.",None
36369159,Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.,2023,"Nicholas, Alan; Schulze, Katja; Johnson, Ann","Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.",ruschv@mskcc.org.
36326731,Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.,2023/Jan/01,"Rhodes, Terence D","Intermountain Healthcare, Salt Lake City, Utah.",None
36282234,"TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.",2023,"Oguchi, Kei; Araki, Hikari; Tsuji, Shingo; Nakamura, Masayuki; Miura, Akihiro; Funabashi, Kaoru; Osada, Akiko; Tanaka, Sakiho; Suzuki, Takamasa; Mizuarai, Shinji","Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.",None
36269795,"Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.",2023/Jan/04,"DaSilva, John; Daly, Christopher","Regeneron Pharmaceuticals, Inc., Tarrytown, New York.; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.",None
36260702,An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.,2023/Jun/27,"List, Alan F","Precision BioSciences, Inc, Durham, NC.",None
36109461,Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery.,2023,"Steffens, Ricarda Carolin; Wagner, Ernst","Pharmaceutical Biotechnology, Center for System-Based Drug Research, Ludwig-Maximilians-Universität, 81377, Munich, Germany.; Pharmaceutical Biotechnology, Center for System-Based Drug Research, Ludwig-Maximilians-Universität, 81377, Munich, Germany. ernst.wagner@cup.uni-muenchen.de.",ernst.wagner@cup.uni-muenchen.de.
35840087,"A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.",2023,"Scott, Emma","Clinical Research Hematology/Oncology, The Janssen Pharmaceutical Companies of Johnson & Johnson, United States.",qbashir@mdanderson.org.
